A new catheter, for at less painful anesthesia procedure when treating varicose veins
CAUTION: For investigational use only. The Solutio catheter has not been evaluated by the FDA and is not available for sale in the USA.
Latest news
MedVasc selected to join accelerator powered by Medtronic
Successful closing of SEK 3 million investment round
Medvasc’s patent portfolio has been granted in key licensing markets
MedVasc selected to join accelerator powered by Medtronic
Successful closing of SEK 3 million investment round
Medvasc’s patent portfolio has been granted in key licensing markets
Changing the anesthesia procedure
With only one injection, instead of several injections through the skin, the Solutio catheter deploys local anesthesia from inside the vein, making the anesthesia procedure less painful for the patient, and more efficient for the clinician. The technology is developed from a clinical need and our first-in-man proved Solutio to be safe to use while significantly lowering pain in the process of deploying local anesthesia prior to performing thermal ablation of varicose veins. The Solutio catheter is compatible with a vast amount of treatment catheters in the market.
The Solutio catheter
Be the first one to try the Solutio catheter, sign up to get more information.
Based on years of experience
It all started with Dr Michael Åkesson, an experienced interventional radiologist, with over 30 years of experience in treating varicose veins, who saw a growing need for pain reduction in the anesthesia procedure prior to treating varicose veins with thermal ablation, such as laser or RF.
While the treatment methods in itself had great and long-lasting results Dr Michael could not let go of the thought of a device that could help clinicians to deploy local anesthesia in a safe, but less painful way.
MedVasc AB was founded in 2013 by Michael Åkesson and has during the last years, developed a final prototype, been granted patents and trademarks in all prioritized markets, and performed a clinical study proving Solutio to be safe to use and significant pain-reduction. During 2023 MedVasc has initiated the FDA 510k process to gain a regulatory pathway towards FDA approval.
